vs
Side-by-side financial comparison of FEDERAL AGRICULTURAL MORTGAGE CORP (AGM) and BillionToOne, Inc. (BLLN). Click either name above to swap in a different company.
FEDERAL AGRICULTURAL MORTGAGE CORP is the larger business by last-quarter revenue ($107.5M vs $83.5M, roughly 1.3× BillionToOne, Inc.). On growth, BillionToOne, Inc. posted the faster year-over-year revenue change (117.4% vs 6.1%).
The Federal Agricultural Mortgage Corporation, also known as Farmer Mac, is a stockholder-owned, federally chartered corporation established by the U.S. Congress in 1988 under the Agricultural Credit Act of 1987. It was created to establish a secondary market for agricultural real estate and housing mortgage loans, to increase liquidity and the availability of long-term, stable credit for farmers, ranchers, and rural communities.
BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.
AGM vs BLLN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $107.5M | $83.5M |
| Net Profit | — | $5.7M |
| Gross Margin | — | 69.9% |
| Operating Margin | 56.3% | 11.5% |
| Net Margin | — | 6.8% |
| Revenue YoY | 6.1% | 117.4% |
| Net Profit YoY | — | 138.3% |
| EPS (diluted) | $3.69 | $0.10 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $107.5M | — | ||
| Q3 25 | $104.0M | $83.5M | ||
| Q2 25 | $102.6M | — | ||
| Q1 25 | $94.3M | — | ||
| Q4 24 | $101.3M | $45.1M | ||
| Q3 24 | $90.3M | $38.4M | ||
| Q2 24 | $89.9M | — | ||
| Q1 24 | $93.7M | — |
| Q4 25 | — | — | ||
| Q3 25 | $55.0M | $5.7M | ||
| Q2 25 | $54.8M | — | ||
| Q1 25 | $49.7M | — | ||
| Q4 24 | $56.5M | $-11.5M | ||
| Q3 24 | $49.8M | $-14.9M | ||
| Q2 24 | $47.1M | — | ||
| Q1 24 | $53.7M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 69.9% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 57.1% | ||
| Q3 24 | — | 52.6% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 56.3% | — | ||
| Q3 25 | 64.1% | 11.5% | ||
| Q2 25 | 63.8% | — | ||
| Q1 25 | 66.9% | — | ||
| Q4 24 | 67.5% | 17.0% | ||
| Q3 24 | 69.0% | -32.9% | ||
| Q2 24 | 65.9% | — | ||
| Q1 24 | 72.8% | — |
| Q4 25 | — | — | ||
| Q3 25 | 52.9% | 6.8% | ||
| Q2 25 | 53.4% | — | ||
| Q1 25 | 52.6% | — | ||
| Q4 24 | 55.8% | -25.5% | ||
| Q3 24 | 55.2% | -38.8% | ||
| Q2 24 | 52.4% | — | ||
| Q1 24 | 57.4% | — |
| Q4 25 | $3.69 | — | ||
| Q3 25 | $4.44 | $0.10 | ||
| Q2 25 | $4.48 | — | ||
| Q1 25 | $4.01 | — | ||
| Q4 24 | $4.62 | $-1.13 | ||
| Q3 24 | $3.86 | $-1.47 | ||
| Q2 24 | $3.68 | — | ||
| Q1 24 | $4.28 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $195.2M |
| Total DebtLower is stronger | $30.8B | $55.0M |
| Stockholders' EquityBook value | $1.7B | $-239.5M |
| Total Assets | $35.4B | $327.5M |
| Debt / EquityLower = less leverage | 17.93× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | $195.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $191.5M | ||
| Q3 24 | $842.1M | — | ||
| Q2 24 | $923.0M | — | ||
| Q1 24 | $745.1M | — |
| Q4 25 | $30.8B | — | ||
| Q3 25 | $29.2B | $55.0M | ||
| Q2 25 | $28.9B | — | ||
| Q1 25 | $28.0B | — | ||
| Q4 24 | $27.5B | $51.5M | ||
| Q3 24 | $27.2B | — | ||
| Q2 24 | $26.8B | — | ||
| Q1 24 | $26.8B | — |
| Q4 25 | $1.7B | — | ||
| Q3 25 | $1.7B | $-239.5M | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.5B | $-251.7M | ||
| Q3 24 | $1.5B | $-242.9M | ||
| Q2 24 | $1.5B | — | ||
| Q1 24 | $1.5B | — |
| Q4 25 | $35.4B | — | ||
| Q3 25 | $33.4B | $327.5M | ||
| Q2 25 | $33.0B | — | ||
| Q1 25 | $31.8B | — | ||
| Q4 24 | $31.3B | $302.1M | ||
| Q3 24 | $30.6B | — | ||
| Q2 24 | $30.2B | — | ||
| Q1 24 | $29.8B | — |
| Q4 25 | 17.93× | — | ||
| Q3 25 | 17.31× | — | ||
| Q2 25 | 18.70× | — | ||
| Q1 25 | 18.39× | — | ||
| Q4 24 | 18.48× | — | ||
| Q3 24 | 18.60× | — | ||
| Q2 24 | 17.87× | — | ||
| Q1 24 | 18.11× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $80.1M | $13.8M |
| Free Cash FlowOCF − Capex | — | $6.5M |
| FCF MarginFCF / Revenue | — | 7.7% |
| Capex IntensityCapex / Revenue | 0.0% | 8.8% |
| Cash ConversionOCF / Net Profit | — | 2.42× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $80.1M | — | ||
| Q3 25 | $74.2M | $13.8M | ||
| Q2 25 | $-47.7M | — | ||
| Q1 25 | $-49.8M | — | ||
| Q4 24 | $612.6M | — | ||
| Q3 24 | $-44.4M | — | ||
| Q2 24 | $56.1M | — | ||
| Q1 24 | $233.3M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $6.5M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $607.4M | — | ||
| Q3 24 | $-44.4M | — | ||
| Q2 24 | $52.6M | — | ||
| Q1 24 | $231.7M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 7.7% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 599.8% | — | ||
| Q3 24 | -49.2% | — | ||
| Q2 24 | 58.5% | — | ||
| Q1 24 | 247.3% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | 8.8% | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 5.2% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 4.0% | — | ||
| Q1 24 | 1.7% | — |
| Q4 25 | — | — | ||
| Q3 25 | 1.35× | 2.42× | ||
| Q2 25 | -0.87× | — | ||
| Q1 25 | -1.00× | — | ||
| Q4 24 | 10.84× | — | ||
| Q3 24 | -0.89× | — | ||
| Q2 24 | 1.19× | — | ||
| Q1 24 | 4.34× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AGM
Segment breakdown not available.
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
